NCT07446569Not yet recruiting
Perception and Integration of Sensory Information in the Early Stages of Psychosis
Source: ClinicalTrials.gov · Last updated 3 Mar 2026
Brief summary (registry, in English)
The goal of this observational study is to investigate the early sensory system in clinical high risk (CHR), first episode psychosis (FEP) individuals and heathly controls. The main questions it aims to answer are: * Can anomalies in visual and auditory sensory processing serve as early markers of psychosis risk? * How are these sensory anomalies related to clinical symptom severity and emotional recognition deficits? Researchers will compare CHR and PEP participants to healthy controls to see if sensory processing differences can help identify individuals at higher risk of developing psychosis. Participants will: * Complete behavioral tasks evaluating visual processing (contrast sensitivity, contour integration, facial emotion recognition, visual inference using Necker cubes) and auditory processing (tone-matching, auditory emotion recognition). A temporal perception component will also be assessed within the auditory and emotion recognition tasks, rather than as a separate task. * Undergo electrophysiological assessments of retinal function using flash stimulation to record retinal potentials (a-wave, b-wave, phNR, oscillatory potentials). * Provide demographic, clinical, and neuropsychological data during study visits. * For CHR participants, attend follow-up visits up to 6 months post initial assessments to evaluate psychotic symptom progression.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 294 (estimated)
- First submitted
- 26 Feb 2026
- Start date
- 1 Apr 2026
- Primary completion date
- 30 Apr 2028
- Lead sponsor
- Centre Psychothérapique de Nancy
- Diseases
- Schizophrenia
- NCT number
- NCT07446569
What you commit to
- Study type: Interventional
- Planned participants: 294
- From 1 Apr 2026 to the primary completion date, 30 Apr 2028
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Impairment that makes participation in the study or understanding of information difficult or impossible
- Current substance use disorder (DAST score \>6)
- Cannabis use disorder (CUDIT-R score ≥13)
- History of neurological disorders, including progressive neurological disease
- Progressive retinal disease
- Ophthalmologic conditions affecting visual acuity
- Current eye infection
- Hearing disorders affecting auditory acuity
- Criteria incompatible with the electroretinographic device:
- Presence of photosensitive epilepsy
- Allergy to components of the electrode gel
Other
- Pregnant, postpartum, or breastfeeding women
- Individuals deprived of liberty by judicial or administrative decision
- Individuals in a life-threatening emergency
- Adults under legal protection measures
- Adults unable to provide consent and not under legal protection
- Alcohol dependence (AUDIT score ≥12 for men, ≥11 for women)
- Chronic glaucoma
- Behavioral problems causing extreme agitation or aggression
- Eye or surrounding tissue lesions that may come into contact with the device
Who the study is looking for
- All groups:
- Age between 18 and 30 years
- Normal or corrected-to-normal visual acuity
- Affiliated with or dependent on a social security health insurance plan
- Provided informed consent and co-signed the study consent form with the investigator
- Proficient in French
- Control group (TEM) specific criteria:
- No current psychiatric disorder (DSM-IV Axis I), except anxiety disorders
- No lifetime history of (hypo)manic episodes or psychotic disorders
- No first-degree family history of schizophrenia spectrum disorders
- No regular use (more than one month continuously) in the past 6 months of the following medications: benzodiazepines, hypnotics, antidepressants, antipsychotics, mood stabilizers, or psychostimulants
- Clinical High-Risk (CHR) group specific criteria:
- -Meet CHR criteria according to CAARMS: Attenuated positive symptoms (APS) below clinical threshold in intensity or frequency OR Brief Limited Intermittent Psychotic Symptoms (SPLI) OR Genetic Risk
- First-Episode Psychosis (PEP) group specific criteria:
- -Meet PEP criteria according to CAARMS (psychosis threshold reached)
Age in the registry: 18 years to 30 years · Sex: All · Accepts healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier Le Vinatier Coordinator of this site? Confirm its status | Bron | France | Unknown status |
| Centre Psychothérapique de Nancy Coordinator of this site? Confirm its status | Laxou | France | Unknown status |
| Centre Hospitalier Alpes-Isère Coordinator of this site? Confirm its status | Saint-Égrève | France | Unknown status |
| Centre Hospitalier Universitaire de Saint Etienne Coordinator of this site? Confirm its status | Saint-Priest-en-Jarez | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.